Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 4;12:2007–2014. doi: 10.2147/PPA.S170054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Taylor et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Factors influencing bDMARD treatment start.

Notes: Physicians could respond with more than one reason. (A) Physician-reported reasons for the choice of first-line bDMARD. Overall N=629. (B) Physician-reported reasons for switching previous bDMARD for current/most recent bDMARD. Overall N=297; physicians could only provide a reason for switching in the 297 patients who received two or more bDMARDs. (C) Physician-reported reasons that would prompt initiation of bDMARD therapy in bDMARD-naïve patients. Overall N=495.

Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; DAS, disease activity score.